The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I:
wherein A, X, Y R
1
, R
2
, R
3
, R
4
, m and n are as described herein.
[EN] PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING<br/>[FR] INHIBITEURS PYRIDILES DE SIGNALISATION HEDGEHOG
申请人:GENENTECH INC
公开号:WO2009126863A2
公开(公告)日:2009-10-15
The invention provides novel inhibitors of hedgehog signaling that are useful as s therapeutic agent for treating malignancies where the compounds have the general formula (I): where A, X, Y R1, R2, R3, R4, m and n are as described herein.
[EN] PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING<br/>[FR] INHIBITEURS PYRIDYLES DE LA SIGNALISATION HEDGEHOG
申请人:GENENTECH INC
公开号:WO2006028958A2
公开(公告)日:2006-03-16
The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y, R1, R2, R3, R4, and n are as described herein.
SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B
申请人:JANSSEN SCIENCES IRELAND UC
公开号:US20150266890A1
公开(公告)日:2015-09-24
Inhibitors of HBV replication of Formula (I)
including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R
1
, R
2
and R
4
have the meaning as defined herein.
The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
申请人:JANSSEN SCIENCES IRELAND UC
公开号:US10676429B2
公开(公告)日:2020-06-09
Inhibitors of HBV replication of Formula (I)
including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R1, R2 and R4 have the meaning as defined herein.
The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.